Welcome to LookChem.com Sign In|Join Free

CAS

  • or

162045-26-3

Post Buying Request

162045-26-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

162045-26-3 Usage

General Description

1-[1-[2-Methoxy-4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]benzoyl]piperidin-4-yl]-2,4-dihydro-1H-3,1-benzoxazin-2-one is a complex chemical compound with a long name. It is a benzoxazinone derivative that contains a piperidin-4-yl and methoxy group, as well as a benzoyl and 2-methyl-1-oxidopyridin-3-ylmethyl substituent. 1-[1-[2-Methoxy-4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]benzoyl]piperidin-4-yl]-2,4-dihydro-1H-3,1-benzoxazin-2-one may have potential pharmaceutical applications, as its structure indicates that it could interact with various biological systems. However, further research and testing would be needed to determine its specific properties and potential uses.

Check Digit Verification of cas no

The CAS Registry Mumber 162045-26-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,2,0,4 and 5 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 162045-26:
(8*1)+(7*6)+(6*2)+(5*0)+(4*4)+(3*5)+(2*2)+(1*6)=103
103 % 10 = 3
So 162045-26-3 is a valid CAS Registry Number.

162045-26-3Downstream Products

162045-26-3Relevant articles and documents

Development of orally active oxytocin antagonists: Studies on 1-(1-{4- [1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy].2methoxybenzoyl}- 4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines

Bell, Ian M.,Erb, Jill M.,Freidinger, Roger M.,Gallicchio, Steven N.,Guare, James P.,Guidotti, Maribeth T.,Halpin, Rita A.,Hobbs, Doug W.,Homnick, Carl F.,Kuo, Michelle S.,Lis, Edward V.,Mathre, David J.,Michelson, Stuart R.,Pawluczy, Joseph M.,Pettibone, Douglas J.,Reiss, Duane R.,Vickers, Stanley,Williams, Peter D.,Woyden, Carla J.

, p. 2146 - 2163 (2007/10/03)

The previously reported oxytocin antagonist L-371,257 (2) has been modified at its acetylpiperidine terminus to incorporate various pyridine N- oxide groups. This modification has led to the identification of compounds with improved pharmacokinetics and excellent oral bioavailability. The pyridine N-oxide series is exemplified by L-372,662 (30), which possessed good potency in vitro (Ki = 4.1 nM, cloned human oxytocin receptor) and in vivo (intravenous AD50 = 0.71 mg/kg in the rat), excellent oral bioavailability (90% in the rat, 96% in the dog), good aqueous solubility (>8.5 mg/mL at pH 5.2) which should facilitate formulation for iv administration, and excellent selectivity against the human arginine vasopressin receptors. Incorporation of a 5-fluoro substituent on the central benzoyl ring of this class of oxytocin antagonists enhanced in vitro and in vivo potency but was detrimental to the pharmacokinetic profiles of these compounds. Although lipophilic substitution around the pyridine ring of compound 30 gave higher affinity in vitro, such substituents were a metabolic liability and caused shortfalls in vivo. Two approaches to prevent this metabolism, addition of a cyclic constraint and incorporation of trifluoromethyl groups, were examined. The former approach was ineffective because of metabolic hydroxylation on the constrained ring system, whereas the latter showed improvement in plasma pharmacokinetics in some cases.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 162045-26-3